Clinical trials are the key means of developing better therapies. At Heartlands, we have been involved in research into HIV since the late 1980s. Research of this sort discovers new drugs, proves new best practice, and improves the treatment of patients in the UK and internationally. Our clinical trials are managed and funded either by pharmaceutical companies, the Medical Research Council or by our own departmental academic staff.
If you are one of our patients, you doctor may ask whether you are interested in taking part in an HIV clinical trial. You’re under no obligation to agree, and if you decide not to it will not affect any care you may already be receiving at Heartlands HIV Service. Below is a list of some of the current trials in which we are currently engaged.
If you would like more information about our trials, or are interested in taking part, please contact our research nurse, Gerry Gilleran, on 0121 424 0644 or at gerry.gilleran@heartofengland.nhs.uk.
Amase – Advancing Migrant Access to health Services in Europe.
Aurah – Attitudes to and Understanding of Risk of Acquisition of HIV. A cross sectional questionnaire study of sexual risk behaviour, attitudes to HIV transmission, antiretroviral treatment for prevention and well being in HIV-negative individuals at risk of HIV-infection recruited from sexual health clinics.
Best Foods For your heart – A randomised controlled pilot study to assess the feasibility of two different dietary interventions for cardiovascular risk reduction in HIV dyslipidaemia. For further information, call Clare Stradling on 0121 424 2881.
Key inclusion criteria:
- Adults with HIV infection
- On stable antiretroviral therapy, with undetectable viral load
- LDL-cholesterol level higher than 3mmol/l
- not on a statin
Cog Uk – A randomised, prospective study, assessing changes in cerebral function in treatment naïve HIV-1 infected subjects commencing either boosted atazanavir with Truvada, or boosted darunavir with maraviroc and Kivexa.
Gilead – A Phase 3, randomized, double-blind study to evaluate the safety and efficiacy of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir 014/111 Alafenamide Verses Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment – Naïve Adults.
Hep C – A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon.
Modern – A multicenter, randomized, double-blind, comparative trial of Maraviroc + Darunavir/Ritonavir Verses Emtricitabine/Tenofovir + Darunavir/Ritonavir for the treatment of antiretroviral naïve HIV infected patients with CCR5 Tropic HIV-1.
Partition – Central Nervous System Penetration of Antiretroviral drugs – The Role of Pharmacogenetic Factors in Variability.
Partner – A study in HIV sero-different partnerships to estimate the rate of transmission of HIV and to investigate factors associated with condom use.
Pivot – Protease Inhibitor monotherapy Verses Ongoing Triple-therapy in the long-term management of HIV disease.
Proud – Pre-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men.
Single – A Phase 3, randomised, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects – ING114467.
Start – Strategic Timing of AntiRetroviral Treatment.